Martin Jacko, PhD
CEO, Aperture Therapeutics
As the CEO of Aperture Therapeutics, Dr. Jacko leads a biotech company that develops novel therapies for age-related neurodegenerative diseases using RNA-based technologies and immunomodulation. He has a strong scientific background and entrepreneurial experience, with a Ph.D. in Pathobiology and Molecular Medicine from Columbia University where he discovered drivers of neuronal maturation, postdoc at Stanford University where he worked on directed evolution techniques, and both platform startup and pharma experience from Serotiny, Inc. and Bridgebio Pharma. He invented multiple high-throughput functional screening platforms that led to discovery of novel drugs.